Geriatric oncology research to improve clinical care.

James Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Nature Reviews Clinical Oncology (Impact Factor: 15.03). 07/2012; 9(10):571-8. DOI: 10.1038/nrclinonc.2012.125
Source: PubMed

ABSTRACT Cancer incidence increases with advanced age. The Cancer and Aging Research Group, in partnership with the National Institute on Aging and NCI, have summarized the gaps in knowledge in geriatric oncology and made recommendations to close these gaps. One recommendation was that the comprehensive geriatric assessment (CGA) should be incorporated within geriatric oncology research. Information from the CGA can be used to stratify patients into risk categories to better predict their tolerance of cancer treatment, and to follow functional consequences from treatment. Other recommendations were to design trials for older adults with study end points that address the needs of the older and/or vulnerable adult with cancer and to build a better infrastructure to accommodate the needs of older adults to improve their representation in trials. We use a case-based approach to highlight gaps in knowledge regarding the care of older adults with cancer, discuss our current state of knowledge of best practice patterns, and identify opportunities for research in geriatric oncology. More evidence regarding the treatment of older patients with cancer is urgently needed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: There is no consensus on the therapeutic approach to poor-risk patients with unresectable stage III non-small cell lung cancer (NSCLC), despite the increasing number of these patients in current clinical practice. In terms of survival, the combination of concurrent systemic therapy with standard radiotherapy might be advantageous over radiotherapy alone. The purpose of this review is to ascertain the feasibility, safety and efficacy of the combination of concurrent systemic therapy and standard radiotherapy in these patients.
    Annals of Oncology 06/2014; · 6.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the aging of our population, the prevalence of prostate cancer is anticipated to rise dramatically. Consequently, physicians will be confronted with the challenges of managing prostate cancer and treatment side effects in older men. The maintenance of mobility and functional independence, which are fundamental goals of the aging patient with cancer, should not be overlooked when choosing treatments and their toxicities focused on cancer control. Consistent with the SIOG (International Society of Geriatric Oncology) guidelines, we recommend standard approaches for older patients with prostate cancer who are fit. Vulnerable patients should also receive standard treatment, provided their health status can be maintained with appropriate interventions. Treatment for frail patients should be adapted to their health status and supportive care interventions should be considered. Individualized treatment plans should take into account patient's remaining life-expectancy from coexisting comorbidities and disability, aggressiveness of the prostate cancer, treatment preferences as well as potential adverse effects of treatment.
    Journal of Geriatric Oncology 09/2014; · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma is a disease of older adults, with two-thirds of patients aged ≥ 65 years and having varying comorbidities, functional status, and cognitive status. Patients ≥ 65 are usually considered ineligible for transplant. The introduction of novel agents, including immunomodulatory drugs such as lenalidomide and proteasome inhibitors such as bortezomib and carfilzomib, has improved treatment tolerance and resulted in improved outcomes for older patients. We present an individualized approach for older patients, “staging” patient age using Comprehensive Geriatric Assessment (CGA) to stratify into fit, unfit and frail groups to guide treatment decisions, including whether or not to transplant, use two-drug versus three-drug combinations, or use reduced-intensity regimens.
    Current Geriatrics Reports. 09/2014; 3(3).


Available from
May 26, 2014